Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Medimaging Integrated Solution Inc. (6796) AI Stock Analysis

TW:6796

Medimaging Integrated Solution Inc.

(TWSE:6796)

Select Model
Rating:42Neutral
Price Target:TWD 47.00â–¼(-4.47% Downside)
Action:initiatedcoverage
Date:11/10/26

The score is primarily constrained by weak cash generation, deteriorating profitability, and rising leverage. Negative technical trends and an exceptionally high P/E ratio further weigh on the assessment, despite strong revenue growth and potentially oversold momentum indicators.

Positive Factors
Revenue AccelerationThe sharp 2025 revenue acceleration shows that the company can expand its top line after a period of stagnation. This stronger revenue base may support operating leverage and investment in imaging solutions, although future benefit depends on restoring profitability and cash conversion.
Negative Factors
Margin CompressionMaterial gross and net margin compression shows that recent sales growth has translated into limited earnings. With net margin near 1.2%, relatively small changes in costs or execution could materially affect profit, restricting internally funded investment and making earnings recovery less dependable.

Medimaging Integrated Solution Inc. (6796) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%30%TW:6796-41.92%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 1.95B
Dividend Yield
0.51%
Average Volume (3M)
62.08K
Price to Earnings (P/E)
123.0
Beta (1Y)
0.36
Revenue Growth
12.26%
EPS Growth
―
Country
TW
Employees
162
Sector
General
Sector Strength
55
Industry
Medical - Devices

Medimaging Integrated Solution Inc. Business Overview & Revenue Model

Company Description

Medimaging Integrated Solution Inc. specializes in delivering advanced digital and mobile diagnostic technology. The company engineers and produces a variety of digital handheld diagnostic scopes, alongside their essential auxiliary equipment. A key...

Medimaging Integrated Solution Inc. Financial Statement Overview

Summary

Strong 2025 revenue growth and positive EBIT are offset by sharply weaker margins, increased leverage, low ROE, and negative operating and free cash flow.

Income Statement

52Neutral

Balance Sheet

48Neutral

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue682.01M661.39M538.92M537.15M502.09M485.87M
Gross Profit265.52M276.55M234.32M307.76M254.39M255.72M
EBITDA65.74M74.50M50.91M119.38M118.98M114.93M
Net Income14.32M7.72M5.61M74.05M70.02M66.48M
Balance Sheet
Total Assets1.65B1.57B1.36B1.34B841.41M715.84M
Cash, Cash Equivalents and Short-Term Investments617.44M546.57M380.18M658.35M335.11M234.26M
Total Debt453.18M674.22M443.15M405.08M87.67M135.50M
Total Liabilities801.99M826.34M613.67M548.13M193.26M229.72M
Stockholders Equity852.27M745.37M742.47M792.50M648.15M486.12M
Cash Flow
Free Cash Flow-73.24M-53.26M-175.90M-30.91M62.05M15.13M
Operating Cash Flow-40.51M-16.16M-50.40M168.42M112.79M45.95M
Investing Cash Flow-204.13M-39.65M7.73M-328.68M-102.63M-19.82M
Financing Cash Flow320.28M219.85M-57.06M359.80M40.36M23.69M

Medimaging Integrated Solution Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:6796 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:6527TW:652773OutperformTWD 1.86B12.15―3.98%-1.23%10.20%
TW:3052TW:305269NeutralTWD 2.12B9.38―5.71%9.24%-3.77%
TW:4138TW:413868NeutralTWD 2.15B15.66―7.75%-1.10%-16.90%
TW:4116TW:411662NeutralTWD 1.82B2.38―4.91%3.85%786.65%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:6796TW:679642NeutralTWD 2.04B123.00―0.51%12.26%―

* General Sector Average

Performance Comparison

-40%-20%0%TW:6796TW:3052TW:4116TW:4138TW:6527TW:7881Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:6796 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:6796Medimaging Integrated Solution Inc.49.20-39.14-44.31%
TW:3052Apex Science & Engineering Corp.10.50-0.24-2.23%
TW:4116BenQ Medical Technology Corp.40.70-2.63-6.06%
TW:4138Dynamic Medical Technologies Inc.54.20-5.23-8.80%
TW:6527Crystalvue Medical Co Ltd72.90-5.53-7.05%
TW:7881Eyecare Tech, Inc.73.20-35.89-32.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026